Literature DB >> 33162303

Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States.

Meghan E McGarry1, Chiung-Yu Huang2, Dennis W Nielson3, Ngoc P Ly3.   

Abstract

BACKGROUND: For unknown reasons, Hispanic patients with cystic fibrosis (CF) have more severe pulmonary disease than non-Hispanic white patients. In CF, the pulmonary pathogen Pseudomonas aeruginosa is associated with worse outcomes. We sought to determine if Hispanic patients with CF are at an increased risk of acquiring P. aeruginosa or acquire it earlier than non-Hispanic white patients.
METHODS: This is a longitudinal study comparing the timing and risk of acquisition of different forms of P. aeruginosa between Hispanic and non-Hispanic white patients aged 0-21 years old with CF in the CF Foundation Patient Registry (CFFPR) in 2008-2013. The age at the initial acquisition of P. aeruginosa (initial acquisition, mucoid, chronic, multidrug-resistant) was summarized using Kaplan-Meier survival curves and analyzed using Cox proportional hazards regression models.
RESULTS: Of 10,464 patients, 788 (7.5%) were Hispanic and 9,676 (92.5%) were non-Hispanic white. Hispanic patients acquired all forms of P. aeruginosa at a younger age than non-Hispanic white patients. Hispanic patients had a higher risk of acquiring P. aeruginosa than non-Hispanic white patients: the hazard ratio (HR) was 1.26 (95% CI 1.16-1.38, p<0.001) for initial P. aeruginosa, 1.59 (95% CI 1.43-1.77, p<0.001) for mucoid P. aeruginosa, 1.91 (95% CI 1.64-2.23, p<0.001) for multidrug-resistant P. aeruginosa, and 1.39 (95% CI 1.25-1.55, p<0.001) for chronic P. aeruginosa.
CONCLUSIONS: Hispanic patients have an increased risk of acquiring P. aeruginosa and acquire it at an earlier age than non-Hispanic white patients in the United States. This may contribute to increased morbidity and mortality in Hispanic patients with CF.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Cystic fibrosis; Health disparities; Pseudomonas aeruginosa

Mesh:

Year:  2020        PMID: 33162303      PMCID: PMC8096863          DOI: 10.1016/j.jcf.2020.10.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  24 in total

1.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

2.  Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.

Authors:  Meghan E McGarry; Susanna A McColley
Journal:  Ann Am Thorac Soc       Date:  2016-10

3.  Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2019-05-29

4.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson
Journal:  J Cyst Fibros       Date:  2012-05-01       Impact factor: 5.482

Review 5.  Asthma disparities in the prevalence, morbidity, and treatment of Latino children.

Authors:  Glorisa Canino; Daphne Koinis-Mitchell; Alexander N Ortega; Elizabeth L McQuaid; Gregory K Fritz; Margarita Alegría
Journal:  Soc Sci Med       Date:  2006-09-07       Impact factor: 4.634

6.  Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.

Authors:  MyMy C Buu; Lee M Sanders; Jonathan A Mayo; Carlos E Milla; Paul H Wise
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

7.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection.

Authors:  C A Demko; P J Byard; P B Davis
Journal:  J Clin Epidemiol       Date:  1995-08       Impact factor: 6.437

9.  The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Authors:  Emily A Knapp; Aliza K Fink; Christopher H Goss; Ase Sewall; Josh Ostrenga; Christopher Dowd; Alexander Elbert; Kristofer M Petren; Bruce C Marshall
Journal:  Ann Am Thorac Soc       Date:  2016-07

10.  Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study.

Authors:  Jason Rho; Chul Ahn; Ang Gao; Gregory S Sawicki; Ashley Keller; Raksha Jain
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

View more
  2 in total

Review 1.  Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Authors:  Meghan E McGarry; Elizabeth R Gibb; Gabriela R Oates; Michael S Schechter
Journal:  Paediatr Respir Rev       Date:  2021-12-22       Impact factor: 5.526

2.  Caregiver burden in cystic fibrosis: a systematic literature review.

Authors:  Conor Daly; Philip Ruane; Karl O'Reilly; Louise Longworth; Gabriela Vega-Hernandez
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 4.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.